By Scott Sznyter

Published in: Pharma Manufacturing

Published on: August 15, 2022

Introduction: Demand for viral vectors used for cell and gene therapies (CGT) is increasing dramatically as hundreds of these novel treatments advance through the clinic towards commercialization. Many challenges must be overcome to ensure the cost-effective manufacturing of these complex biomolecules, including selecting the right solutions for packaging, storage and transport of these expensive and potentially lifesaving products.

Advance Stability Knowledge

Would you like to see a particular publication, guidance, organization, supplier, event, or career opportunity on StabilityHub? Contact us with your suggestion!